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A B S T R A C T 
Background: Liver cancer remains to grow worldwide. We aimed to describe the period 
prevalence (PP) and incidence rates (Irs) for liver cancer in Isfahan Province that is 
located in the center of Iran and ranked as the third province in terms of population. 
 
Methods: Information related to the Surveillance, Epidemiology, and End Results; 
(SEER) was collected from the Isfahan Cancer Registry. Period prevalence (PP) was 
calculated per 100,000 people. The cancer sites studied were defined according to the 
International Classification of Diseases (ICD-O; Third Edition) and recorded by 
topography code (C22). 
 
Result: Among all registered liver cancer patients, 57% of the 920 cases were male. The 
mean age of the patients was 65.9 ± 16.8 years. Reported age in 13% of the patients 
was less than 50 years and as high as 84% were in between 50 to 90 years. With a total 
PP of 18.5 per 100,000 people, this value was 24.4% higher in males when compared to 
females (16.8 vs. 20.9). In the previous years, incidences were 3.9 (2011-2012), 5.3 
(2012-2013), 4.9 (2013-2014) and 4.2 (2014-2015) per 100,000 people. There were 89% 
reported deaths among the total population. 
 
Conclusion: The PP for liver cancer in male population was approximately 24.4% higher 
than females. There was a 7.7% increase in the Irs over the study period. Further study 
toward estimation of the proportion of the causes of liver cancer and deaths due to 
infection of hepatitis B and C virus, exposure to aflatoxin, alcohol drinking and smoking 
seem to be advantageous. Therefore, the plan of healthcare system should focus on 
greater effort toward strategic evidence-based pharmacotherapy in Isfahan 
province/Iran. 
 
 
 
INTRODUCTION 
 
According to previous published articles, primary liver 
cancer (LC) was one of the most frequently occurring 
cancer in the world and the second largest contributor 
to cancer mortality. The prevalence and incidence of 
diseases related to liver seems to show similar picture 
but there are variation related to trend in risk factors. 
Globally, the most common histology in LC is 
hepatocellular carcinoma (HCC; 80%), a tumor of the 
parenchymal cells of the liver. The second most 
common histology is intrahepatic cholangiocarcinoma 
(ICC; 15%), which arises in the cholangiocytes of the 
intrahepatic bile duct. Large geographic disparities in 
incidence and mortality of all types of liver cancer exist 
(1-6). Besides many causes, hepatocellular carcinoma 
could also be the result of chronic liver disease in 
patients with non-alcoholic fatty liver disease (7). 
Related to the world’s burden of diseases, report 
confirms a 75% occurrence of disease in Asia, with China 
accounting for over 50%. Northern Europe, the Middle 
East, Oceania, North and South America were marked as 
the countries with the lowest incidence rates. Mongolia 
was reported as the country with the highest age-
standardized incidence rate of 78.1 per 100,000 people 
(5). 
Isfahan province covers approximately 107,027 km2 
and is located in the center of Iran, a country in 
Southwest Asia. Isfahan province ranked as the third 
province in terms of population (498,210 people) after 
Tehran and Mashahad. Between the years of 2003 to 
2009, a published study confirmed that there were 
3,584 cases of liver cancer in Iran (8). Another article in 
the year of 1990 and 2015 reported that distinct age 
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standardized LC incidence rate were 1.56 in female 
versus 2.03 in male per 100,000 people in Iran (9). 
According to a published article, the mortality of liver 
cancer has changed, as the rate of death has increased 
from 4.78 (2006) to 5.37 (2010) in Iran (10). Studies in 
2012 that include all registered Iranian cancer cases 
confirmed 1,567 patients with liver cancer 
corresponded to a crude rate of 2.1 and a standardized 
rate of 2.5 per 100,000 people (11). 
In order to develop the existed technical approach, 
understanding epidemiology of liver cancer could lead 
to improved pharmacotherapy or surgical management. 
Therefore, this study aimed to investigate the period 
prevalence and incidence rates of liver cancer in Isfahan 
Province Iran. 
 
MATERIAL AND METHOD 
 
The study was conducted in the Isfahan Kidney 
Transplantation Research Centre (IKTRC). This 
retrospective survey was a part of a project that was 
approved by the Institutional Review Board (No. 
295115). The Isfahan Cancer Program is intended to 
record all cancer cases in Isfahan. All pathology centres 
and other information sources such as hospital medical 
records, mortality data provinces, haematology-
oncology centres, radiotherapy centres, are obliged to 
report their data to the Isfahan Cancer Office of Disease 
Control and Prevention (CDC). The management arm of 
the program is the deputy of research in the Isfahan 
University of Medical Sciences. The cancer sites studied 
were defined according to the International 
Classification of Diseases (ICD-O; Third Edition). Liver 
cancer was defined by topography code (C22). The 
inclusion criteria were associated to all recorded cases 
with liver cancer and there were not any exclusion 
criteria. 
Data, with linkage to using of the de-identified patient 
name and surname, demographic such as age and 
gender, final code for cancer diagnosis and date of the 
diagnosis were recorded. 
The total population for Isfahan province was 
obtained from the Isfahan Program and Budget 
Management Organization. Period Prevalence was 
calculated as the proportion of total cases over the 
period in year 2011 and 2015 to population at risk 
during the same period of time x 100,000. Incidence 
rates (Irs) was calculated by dividing new cases of 
cancer during a given time period to population at risk 
during the same period of time x 100,000. The statistical 
analysis of d-Base was performed using Microsoft Excel 
and SPSS v. 20 (Chicago, IL, USA) for windows (2,3). 
 
 
 
RESULTS 
 
There were 920 recorded cases, in which 57% were 
males. The normality distribution of age was tested by 
the Kolmogorov-Smirnov test and to show continuous 
variable, the data was shown as mean ± standard 
deviation (SD). The mean (SD) age was 65.9 (16.8) years.  
As shown in Figure 1, the most incident of liver cancer 
(83%) occurred between the ages of 50 to 90 years old. 
Demographic and epidemiology characteristic of 
patients with liver cancer are shown in Table 1. 
 
Table 1. Demographic and epidemiological characteristics of 
the patients with liver cancer 
      
Ir (%) 
Population 
studied 
N 
RLC, 
n 
RD, 
n 
Age, year, 
mean (SD) 
PP 
2011–
2012 
2012–
2013 
2013–
2014 
2014–
2015 
Total 920 105 815 65.9(16.8) 18.5 3.9 5.3 4.9 4.2 
Females 393 42 351 65.2(17.0) 20.9 3.4 4.3 4.6 3.6 
Males 527 63 464 66.4 (16.6) 16.0 4.6 6.3 5.3 4.7 
RLC: reported living cases, RD: reported death, PP: period prevalence, 
Ir: Incidence rate. 
 
 
Figure 1. Distribution of age in patients with liver cancer 
 
The calculated PP was 18.5 per 100,000 people, which 
corresponded to a PP of 16.8 per 100,000 in females 
and 20.9 per 100,000 in males. Figure 2 shows the Irs for 
liver cancer between the year of 2011–2015 associated 
to each gender. 
 
 
Figure 2. Incidence rate of liver cancer associated to gender 
 
ZAHRA TOLOU-GHAMARI*, FARHAD TADAYON, HAMID MAZDAK    58 
 
 
 
 
www.indonesianjournalofcancer.or.id 
The Irs for the related years of study for both genders 
comprised of females vs. males were: 3.9 (3.4 vs. 4.6), 
5.3 (4.3 vs. 6.3), 4.9 (4.6 vs. 5.3) and 4.2 (3.6 vs. 4.7) per 
100,000 people. Out of total population studied 
(n=920), 815 (89%) were reported; that corresponded to 
351 deceased females and 464 males respectively. 
 
DISCUSSION 
 
On the global scale, hepatocellular carcinoma was 
reported as a major contributor to both cancer 
incidence and mortality (5). The incidence could be 
explained by the distribution and natural history of the 
hepatitis B and C viruses (6). More than 240 million 
individuals worldwide are infected with chronic 
hepatitis B virus (HBV). Among individuals with chronic 
HBV infection who are untreated, 15% to 40% progress 
to cirrhosis, which may lead to liver failure and liver 
cancer (14). 
In this study, the total PP for liver cancer in Isfahan 
province was 18.5 per 100,000 persons that 
corresponded to a value of 20.9 for males and 16.8 for 
females. This is consistent with published articles that 
also confirmed higher values in males (15). Age reported 
liver cancer was 13% in patients less than 50 years and 
as high as 84% between 50 to 90 years. Previous 
publication confirmed that the age-dependent patterns 
in the gender difference in the incidence of 
hepatocellular carcinoma support the hypothesis of a 
protective role of estrogens16. In the United States, 
liver cancer was reported as the fastest increasing 
cancer and is one of the leading causes of cancer-
related death in New York City, with wide disparities 
among neighborhoods (16). Experimental and molecular 
epidemiological studies indicate important roles for 
changes in insulin signaling, adipose tissue-derived 
inflammation and sex hormone pathways in mediating 
the association between adiposity and gastrointestinal 
cancer (17). This study is similar to previous study that 
mentioned liver cancer as one of the most common 
causes of death in the world (18). 
In congruence with previous publication, 
gastrointestinal cancers remain the most prevalent 
cancer in many developing countries such as Iran. An 
upward trends in age adjusted incidence (males 22.9 to 
74.2 and females 14.9 to 44.2), prevalence (males 52.6 
to 177.7 and females 38.3 to 111.03), and mortality 
(males 14.6 to 47.2 and females 9.6 to 28.2) rates per 
100,000 people for the period of 2001 to 2010 was 
reported (17). There were 89% reported death among 
all 920 patients with liver cancer. Cigarette smoking, 
particularly recent smoking, knowingly augmented 
mortality risk from liver cancer (18). HBV, HCV, 
aflatoxin, alcohol drinking and tobacco smoking could 
be responsible for liver cancer mortality and incidence 
too (19).  
Finally, the result of this study confirmed a 7.7% 
increase in the incidence rate of liver cancer over the 
study period. Due to the presence of different 
categories of socio-economic, behavioral and ecological 
risk factors regarding access to specialized 
pharmacotherapy and surgical facilities (20-21), further 
study toward dissimilar structures associated to liver 
cancer management in Isfahan Province/Iran seem to be 
advantageous. Therefore authorities can use this data 
for scheduling health care and assigning incomes in 
public health. 
 
CONCLUSION 
 
The PP for liver cancer in male population was 
approximately 24.4% higher than females. There was a 
7.7% increase in the Irs over the study period. Further 
study toward estimation of the proportion of the causes 
of liver cancer and deaths due to infection of hepatitis B 
and C virus, exposure to aflatoxin, alcohol drinking and 
smoking seem to be advantageous. Therefore, the plan 
of healthcare system should focus on greater effort 
toward strategic evidence-based pharmacotherapy in 
Isfahan province/Iran. 
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